Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONO 6126

Drug Profile

ONO 6126

Alternative Names: DE-103; ONO-6126

Latest Information Update: 25 Mar 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ono Pharmaceutical
  • Developer Santen Pharmaceutical
  • Class Anti-inflammatories; Antiasthmatics; Bronchodilators
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Allergic conjunctivitis; Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 23 May 2008 Phase-II clinical trials in Allergic conjunctivitis in Japan (Ophthalmic)
  • 30 Apr 2006 Discontinued - Phase-II for Chronic obstructive pulmonary disease in North America (PO)
  • 28 Mar 2006 ONO 6126 has been licensed to Santen Pharmaceutical for ophthalmic use in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top